Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26727305 | 1.00 | HRH3 (0.36) | HRH3ALDH1A1KCNH2CYP2D6MAPT | |
| SCHEMBL26205503 | 1.00 | HRH3 (0.36) | HRH3ALDH1A1KCNH2CYP2D6MAPT | |
| SCHEMBL26723932 | 0.85 | HRH3 (0.33) | HRH3ALDH1A1KCNH2CYP2D6 | |
| SCHEMBL26723938 | 0.85 | HRH3 (0.33) | HRH3ALDH1A1KCNH2CYP2D6 | |
| SCHEMBL26723933 | 0.85 | HRH3 (0.33) | HRH3ALDH1A1KCNH2CYP2D6 | |
| SCHEMBL14558079 | 0.85 | ALDH1A1 (0.36) | HRH3ALDH1A1KCNH2CYP2D6MAPT | |
| SCHEMBL19090791 | 0.82 | MAPT (0.36) | HRH3MAPT | |
| SCHEMBL19880558 | 0.80 | GABRR1 (0.39) | ALDH1A1MAPT | |
| SCHEMBL19879502 | 0.80 | GABRR1 (0.39) | ALDH1A1MAPT | |
| SCHEMBL19769002 | 0.80 | GABRR1 (0.39) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | HRH3 994/4885ALDH1A1 4236/4885KCNH2 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.